Aprea logo 445pt.png
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
September 08, 2022 08:00 ET | Aprea Therapeutics
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
Aprea logo 445pt.png
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
August 11, 2022 16:15 ET | Aprea Therapeutics
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
Aprea logo 445pt.png
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations
March 15, 2022 16:15 ET | Aprea Therapeutics
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022
January 06, 2022 08:00 ET | Aprea Therapeutics
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea logo 445pt.png
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting
December 14, 2021 08:00 ET | Aprea Therapeutics
BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH...
Aprea logo 445pt.png
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
December 09, 2021 08:00 ET | Aprea Therapeutics
BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea logo 445pt.png
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
November 08, 2021 16:15 ET | Aprea Therapeutics
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea logo 445pt.png
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
September 14, 2021 08:00 ET | Aprea Therapeutics
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
August 12, 2021 16:15 ET | Aprea Therapeutics
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea logo 445pt.png
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
August 12, 2021 06:00 ET | Aprea Therapeutics
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...